News
NPCE
15.23
-2.81%
-0.44
Analysts’ Top Healthcare Picks: Oncolytics Biotech (ONCY), NeuroPace (NPCE)
TipRanks · 4h ago
Weekly Report: what happened at NPCE last week (0202-0206)?
Weekly Report · 9h ago
Weekly Report: what happened at NPCE last week (0126-0130)?
Weekly Report · 02/02 09:18
Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock
Benzinga · 01/27 13:00
NeuroPace Price Target Raised to $19.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 01/27 11:29
NeuroPace Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 01/27 11:29
NEUROPACE, INC. <NPCE.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $19 FROM $18
Reuters · 01/27 11:07
NeuroPace price target raised to $19 from $18 at H.C. Wainwright
TipRanks · 01/27 11:05
Weekly Report: what happened at NPCE last week (0119-0123)?
Weekly Report · 01/26 09:18
Weekly Report: what happened at NPCE last week (0112-0116)?
Weekly Report · 01/19 09:20
Analysts Are Bullish on Top Healthcare Stocks: Glaukos (GKOS), Rapid Micro Biosystems (RPID)
TipRanks · 01/14 13:50
Morning Movers: L3Harris Technologies jumps after DoW investment
TipRanks · 01/13 14:01
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
TipRanks · 01/13 12:41
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
TipRanks · 01/13 12:40
NeuroPace sees Q4 revenue of about $26.6M
Seeking Alpha · 01/13 12:39
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
TipRanks · 01/13 12:35
*NeuroPace, DIXI Medical Entered an Amendment to Distribution Agreement to End Wind Dn Period and Cease Comml Partnership Activities on Dec 31, Earlier Than Previously Agreed Period Ending March 31, 2026 >NPCE
Dow Jones · 01/13 12:33
*NeuroPace Is Currently Selling Back, at Cost, Remaining DIXI Inventory to DIXI Medical, Which Is Expected to Be Completed Before Close of 1Q >NPCE
Dow Jones · 01/13 12:33
*NeuroPace Sees FY26 Rev $98M-$100M >NPCE
Dow Jones · 01/13 12:32
Neuropace Projects Up to $100 Million Revenue in 2026 Outlook
Reuters · 01/13 12:31
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.